Document Detail


Current status of the Xience V® everolimus-eluting coronary stent system.
MedLine Citation:
PMID:  20936921     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The introduction of drug-eluting stents has led to a marked reduction of restenosis, which is a major limitation of percutaneous coronary intervention for coronary artery disease. The next-generation Xience V® (Abbott Vascular, CA, USA) everolimus-eluting stent was designed to address the limitations of first-generation drug-eluting stents. The cobalt-chromium stent platform with an open-cell design offers excellent deliverability. Moreover, the combination of a thin fluoropolymer eluting the antirestenotic drug everolimus provides both an effective suppression of neointimal tissue and rapid re-endothelialization above and between stent struts in preclinical studies. Large randomized clinical trials comparing the everolimus-eluting stent with the Taxus Express® and Liberté® (Boston Scientific, MA, USA) paclitaxel-eluting stents have shown reduced rates of repeat revascularization, myocardial infarction and stent thrombosis at 1-year follow-up with the everolimus-eluting stent. However, we will have to await long-term (5-year) data from these randomized clinical trials with the everolimus-eluting stent to determine whether the observed benefit is robust. Furthermore, data are currently limited the clinical performance of the everolimus-eluting stent relative to drug-eluting stents other than the Taxus Express and Liberté paclitaxel-eluting stents, although a large number of trials are now being conducted to address these questions. In this article, we provide a comprehensive overview of (pre)clinical studies with the everolimus-eluting stent.
Authors:
Bimmer E Claessen; Adriano Caixeta; José P S Henriques; Jan J Piek
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-12     Completed Date:  2011-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1363-74     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon, Coronary / methods
Animals
Coronary Artery Disease / therapy*
Coronary Restenosis / etiology,  prevention & control
Drug-Eluting Stents*
Humans
Myocardial Infarction / epidemiology,  etiology
Randomized Controlled Trials as Topic
Sirolimus / administration & dosage,  analogs & derivatives*
Thrombosis / epidemiology,  etiology
Chemical
Reg. No./Substance:
159351-69-6/everolimus; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The biomechanical analysis of relative position between implant and alveolar bone: finite element me...
Next Document:  7th meeting on hypertension and atherosclerosis.